Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Nichi-Iko Recalls 2 Products over Quality Issues Days after Biz Suspension Lifted
Nichi-Iko Pharmaceutical launched voluntary recalls for generic versions of two allergy drugs Allelock (olopatadine) and Xyzal (levocetirizine) over quality issues on April 8, just days after it came out of a manufacturing suspension at its major plant. Olopatadine OD Tablets…
To read the full story
Related Article
BUSINESS
- Sanofi Files Venglustat for Gaucher Disease in Japan
June 29, 2026
- Toho Shareholders Approve Trigger for 3D Defense Measures
June 29, 2026
- Nippon Shinyaku Bags Option on Elixirgen’s DMD Candidate
June 29, 2026
- UK Accepts Taletrectinib Filing for ROS1+ NSCLC: Eisai
June 29, 2026
- Takeda Files XFG-Adapted COVID Vaccine in Japan
June 29, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…